Day 3 :
- Analysis of Nutraceuticals and Functional Food Ingredients
Dietary supplements and Functional Beverages
Probiotics and Prebiotics
Session Introduction
Mark J S Miller
Healthy Directions, USA
Title: Nutrient – microbiome interactions: Historical considerations and future trends
Time : 10:00-10:35
Biography:
Mark J S Miller is a unique, innovative and entrepreneurial scientist with a heady track record of success in business. With three decades of experience as a Professor and elite researcher, Dr. Miller currently approaches unmet consumer needs using the opportunities offered by natural products and nutrition. His product innovations, marketing skills and ground-breaking research has crossed numerous disciplines offering a unique scientific and global perspective.
Abstract:
Taking the now established concept that as individuals we are a community, an individual can be defined as a collective of our own mammalian cells, in addition to the litany of different microbes that live on us, and in us. Approaching “self†as a community allows for us to better appreciate health and disease. We need to think beyond systems and changes in receptors/enzymes and related targets for drugs in the 20th century, to consider cellular approaches to health. In other words, what we can do to control the make-up and function of our community as a driver for health. Nutrition can play a huge part because the type of food, as well as quantity, can dictate the function and form of our bacterial community. The old adage “you are what you eat†takes on a very specific meaning. Using research examples stemming from neonates, who are the commencement of colonization, and therefore becoming their true entities, to societies who have not been exposed to antibiotics and different diets, to the chronic health issues on modern societies, we can draw attention to a critical determinant of health and disease, namely nutrient-microbiome interactions.
Natarajan Ranganathan
Kibow Biotech Inc. USA
Title: The concept and potential of enteric dialysis, the gut – Kidney connection
Time : 10:55-11:30
Biography:
Natarajan Ranganathan has been a medical researcher and entrepreneur for over thirty years. He earned two master’s degrees (organic chemistry and biochemistry) from the University of Poona, India and obtained a Ph.D. in Bio-organic chemistry from Temple University, Philadelphia. He received further academic training at the University of Pennsylvania, Hahnemann Medical College, Philadelphia, and Johns Hopkins Medical Institutions, Baltimore. Dr. Natarajan Ranganathan (Dr. Rangan), is the key founder and Managing Director (R&D) of Kibow Biotech Inc. located in Newtown Square, PA – USA. He has published more than 25 papers in reputed journals.
Abstract:
The primary goal of this talk is to update recent scientific progress, understanding, knowledge gained and also several clinical advances made since the very first review that was published in the year 2012 (Title: Probiotics, Prebiotics and Synbiotics: Gut and Beyond in Gastroenterology Research and Practice). The use of probiotics and prebiotics is generally well recognized towards digestive, gut and immune health. However, Kibow Biotech is a R&D Biotech company involved in novel and niche application of probiotics and prebiotics as a dietary supplement in stabilization of Gut Microbiome towards Chronic Kidney Disease (CKD). Since our first review article, several other reviews have been published. These independent reviews in various scientific journals reflect various topics such as gut Microbiome, its dysbiosis, impact of the altered intestinal characteristics including small bowel bacterial overgrowth, newer uremic toxins, adsorbent drugs and several observational small scale clinical studies from us and a host of others. This talk mainly connects various aspects of scientific understanding with greater emphasis on the health economics and potentials of probiotics and prebiotics towards CKD applications both in developed and developing countries. Thus, the speaker has undertaken to revisit, review and offer his independent views in connecting the failing kidney function by the bowel. This original concept is now being more scientifically researched, commercially validated and realized as “Gut and Kidney connection”.
Devanand Luthria
U.S. Department of Agriculture, USA
Title: Influence of sample preparation and processing on the assay of phenolic phytochemicals in foods
Time : 12:05-12:40
Biography:
Devanand Luthria (Dave) is a Research Chemist in Food Composition and Methods Development Lab of the United States Department of Agriculture (USDA) Agricultural Research Service.
Abstract:
Phenolic phytochemicals are ubiquitously distributed throughout the plant kingdom and have been well studied for their bioactivities. Phenolic phytochemicals exist in multiple forms (free, conjugated, and bound insoluble). Hence, their accurate quantification is challenging. This presentation will discuss the significance of sample preparation and processing in the assay of phenolic phytochemicals in different food matrices. Systematic analysis of sequential pearled fractions of grains, potato peels and onion layers showed that phenolic compounds are not uniformly distributed in foods. The concentration of phenolic phytochemicals in the outermost layers was significantly higher than the inner edible portion. Similarly, sequential pearling of grains showed gradual decrease in phenolic compound concentration with an increase in the degree of pearling. Evaluation of optimization of different sample preparation parameters showed that particle size, solvent composition, solid-to-solvent ratio, and temperature have significant influence on the yield of phenolic compounds extracted from grains, vegetables, and dietary supplements. The results also showed that most phenolic acids existed in the bound insoluble form in grains. Around 50% of the phenolic acids were recovered in the initial three pearling fine fractions (within ~20% surface removal). Thus, an understanding of the distribution of phytochemicals and optimization of sample preparation procedures are important for accurate analysis and evaluation of their bioactivities.
Lisa Stehno Bittel
LikardaBio, LLC
Title: Efficacy and toxicity testing in 3D tissue models provides improved outcomes
Biography:
Lisa Stehno-Bittel began her career in healthcare as a physical therapist. With more than 25 years of research experience in the fields of cell biology and diabetes, she has over 60 publications in scientific journals and has received more than $9 million in grant funding for her research. Lisa is on faculty at the University of Kansas Medical Center and serves as President and Founder of Likarda, LLC. She has a BS degree from the University of Kansas, a PhD from the University of Missouri and completed a pharmacology fellowship at the Mayo School of Medicine. Lisa has received numerous awards including the Outstanding Faculty Research Award from the University of Kansas Medical Center and the Jim Baxendale Commercialization Award.
Abstract:
Efficacy and toxicity testing are key to understanding the effects of any nutraceutical compound in the body. Research has shown that in vitro testing done in 3D tissue models is superior to traditional 2D cell culture. We have patented an efficient method of creating and testing 3D cellular models for a variety of tissues including oral health, metabolic function and diabetes, and 12 different types of cancer. For our clients we have compared the nutraceutical product, Triology, to competitive mouth rinses, showing that Triology was less toxic to healthy gum tissue and more efficacious in killing bacteria. Studies of the insulin-producing islet clusters showed that our 3D tissue model outperformed by 2.5 times intact human tissue from donors in predicting which compounds would work best in the body. Likewise, the diabetes drug glybenclamide had a greater response in the 3D tissue model than on native human islets or cells grown in 2D culture. The same trend was noted when testing the effect of a nutraceutical product on miniaturized cancer tumors. The proprietary nutraceutical compound showed better effects in the 3D tissue model. The same was true for standard chemotherapies like paclitaxel, which had no effect on ovarian cancer cells grown in a monolayer, but strongly killed those same cells when they were grown in 3D (60% cell death a 100 ïM dose). We have tested efficacy and toxicity assays on over 100 different nutraceutical compounds using the 3D tissue model, improving the predictability of the test for in vivo outcomes.
Biography:
Lisa Stehno-Bittel began her career in healthcare as a physical therapist. With more than 25 years of research experience in the fields of cell biology and diabetes, she has over 60 publications in scientific journals and has received more than $9 million in grant funding for her research. Lisa is on faculty at the University of Kansas Medical Center and serves as President and Founder of Likarda, LLC. She has a BS degree from the University of Kansas, a PhD from the University of Missouri and completed a pharmacology fellowship at the Mayo School of Medicine. Lisa has received numerous awards including the Outstanding Faculty Research Award from the University of Kansas Medical Center and the Jim Baxendale Commercialization Award.
Abstract:
Efficacy and toxicity testing are key to understanding the effects of any nutraceutical compound in the body. Research has shown that in vitro testing done in 3D tissue models is superior to traditional 2D cell culture. We have patented an efficient method of creating and testing 3D cellular models for a variety of tissues including oral health, metabolic function and diabetes, and 12 different types of cancer. For our clients we have compared the nutraceutical product, Triology, to competitive mouth rinses, showing that Triology was less toxic to healthy gum tissue and more efficacious in killing bacteria. Studies of the insulin-producing islet clusters showed that our 3D tissue model outperformed by 2.5 times intact human tissue from donors in predicting which compounds would work best in the body. Likewise, the diabetes drug glybenclamide had a greater response in the 3D tissue model than on native human islets or cells grown in 2D culture. The same trend was noted when testing the effect of a nutraceutical product on miniaturized cancer tumors. The proprietary nutraceutical compound showed better effects in the 3D tissue model. The same was true for standard chemotherapies like paclitaxel, which had no effect on ovarian cancer cells grown in a monolayer, but strongly killed those same cells when they were grown in 3D (60% cell death a 100 ïM dose). We have tested efficacy and toxicity assays on over
- Symposium
Session Introduction
Prof. Sinerik Ayrapetyan
UNESCO Chair- Life Sciences International Postgraduate Educational Center, Armenia
Title: Healthy food for decreasing the risk of age-related disorders
Biography:
Prof. Sinerik Ayrapetyan has completed his Ph.D in Cell Biophysics in the Institute of Physiology of Ukraine Academy of Sciences, Kiev. He is the head and coordinator of Research Council of Life Sciences International Postgraduate Educational Center and UNESCO Chair in Life Sciences in Yerevan, Armenia. His current research interest is “Intracellular Signalling System in Norm and Pathology”. On this subject he has published more than 7 international books and 115 papers in refereed journals. He is serving as a member of the board of associate editors for the journals: "Electromagnetic Biology and Medicine" "Journal of International Dental and Medical Research", “ISRN Biophysics” and member of editorial board of the journals: “Advances in Life Sciences", “Bioavailability and Bioequivalence”, “Applied Pharmacy”, “European Journal of Biophysics”, “Biochimica et Biophysica Acta”. He is a member of International Coordination Council of WHO and number of professional international societies.
Abstract:
Age-induced medical disorders are modern problems in medicine and have become a focal point for public health concern due to the aging of the world population. The main barrier for solving this problem is, in the literature available for us, the absence of a reliable, universal biomarker for detection of the functional state of the whole organism though there are different methods for detection of the functional state of individual organs. We believe that metabolic controlling of cell hydration could serve as a universal biomarker for estimation of the effect of different chemical and physical factors, including food and drinking water, on the functional state of the organism. By our previous study it was shown that cell pathology, including aging, leads to the dysfunction of Na+/K+-ATPase α3 isoform-dependent intracellular signaling system controlling cell hydration. Therefore, we suggest that that activation of α3 isoform-dependent cell hydration could serve as a marker for estimation of bioavailability of food and drinking water. For this purpose, elaboration of a new non-invasive device with corresponding software for detection of muscle hydration based on frequency-dependent characteristics of muscle impedance is suggested. The experimental data that prove our suggestion will be demonstrated in the lecture.